The role of CD4+ T-cells in the development of MS

Neurological Research

Volumn 28, Issue 3, 2006, Pages 245-249

  Delgado, Sylvia ^a   Sheremata, William A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CD4+ T cells; Cytokines; Immunopathogenesis; MS, autoimmunity; Multiple sclerosis

Indexed keywords

CD4 ANTIGEN;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS;

EID: 33646814688     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X98107     Document Type: Review

References (34)

1. Liblau RS, Fontaine B. Recent advances in immunology in multiple sclerosis. Curr Opin Neurol 1998; 11: 293-298
2. Jacobson S. Association of human herpesvirus 6 and multiple sclerosis: Here we go again? J Neurovirol 1998; 4: 471-473
3. Trapp BD, Peterson J, Ransonhoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285
4. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717
5. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952
6. Janeway C, Travers P, Walport M, Shlomchik M, eds. Immunobiology: The Immune System in Health and Disease, 5th edn, New York, NY: Garland Publishing, 2001
7. Croxford JL, Olson JK, Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev 2002; 1: 251-260
8. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-187
9. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579-621
10. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747
11. Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000; 12: 413-418
12. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through 1L-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549
13. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-808
14. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nature Immunol 2000; 1: 199-205
15. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cells responses: The alternative approaches. Annu Rev Immunol 1997; 15: 297-322
16. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45 (6 suppl. 6): S11-S15
17. Panitch H, Hirsch RL, Haley AS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-895
18. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: The role of T cells. Curr Opin Neurol 1999; 12: 309-321
19. Bonetti B, Raine CS. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997; 42: 74-84
20. Chofflon M, Roth S, Juilliard C, et al. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur Cytokine Netw 1997; 8: 253-257
21. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582
22. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: A crucial re-appraisal. Trends Immunol 2004; 25: 132-137
23. Ufret-Vincenty RL, Quigley L, Tresser N, et al. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis. J Exp Med 1998; 188: 1725-1738
24. Wekerle H, Hohlfeld R. Molecular mimicry in multiple sclerosis. N Engl J Med 2003; 349: 185-186
25. Bray PF, Luka J, Bray PF, et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992; 42: 1798-1804
26. Sheremata WA, Minagar A, Alexander JS, et al. The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs 2005; 19: 909-922
27. Gay FW, Drye TJ, Dick GW, et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120: 1461-1483
28. Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144-160
29. Miller DJ, Njenga MK, Murray PD, et al. A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. Int Immunol 1996; 8: 131-141
30. Ciric B, Howe CL, Paz Soldan M, et al. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003; 13: 608-616
31. Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: Structure, signaling, and roles in nervous system development and functions. J Neurochem 2000; 75: 2227-2240
32. Krieglstein K, Strelau J, Schober A, et al. TCP-beta and the regulation of neuronal survival and death. J Physiol Paris 2002; 96: 25-30
33. Miller DH, Khan O, Sheremata W, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23
34. Polman CH, O'Connor PW, Hardova F, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910